Kiniksa Pharmaceuticals International, plc key statistics and ratios

In fiscal 2025, Kiniksa Pharmaceuticals International, plc had return on equity of 11.7%, an operating margin of 11.4%, debt equal to 0.0% of equity and a current ratio of 3.79. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kiniksa Pharmaceuticals International, plc: financial ratios, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Gross margin	76.4%	89.6%	87.6%	85.6%	88.5%	90.2%
Operating margin	−406.4%	4.4%	−9.3%	−10.8%	11.4%	13.8%
Net margin	−409.7%	83.3%	5.2%	−10.2%	8.7%	11.6%
Free-cash-flow margin	−328.7%	2.6%	4.9%	6.0%	20.1%	20.8%
Return on equity	−85.3%	63.1%	3.4%	−9.8%	11.7%	17.1%
Return on assets	−67.8%	53.0%	2.9%	−7.8%	8.8%	12.5%
Asset turnover	0.17	0.64	0.55	0.76	1.01	1.08
Current ratio	4.38	5.16	4.34	3.30	3.79	3.91
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Effective tax rate	—	—	—	—	33.6%	25.0%
R&D as % of revenue	257.6%	29.7%	28.2%	26.4%	14.3%	14.4%
SG&A as % of revenue	223.0%	44.5%	47.9%	39.7%	29.0%	26.1%
Capital spending as % of revenue	1.1%	0.0%	0.0%	0.1%	0.2%	0.2%
Free cash flow ÷ net income	—	3.1%	93.5%	—	231.2%	180.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Kiniksa Pharmaceuticals International, plc: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Gross margin	85.4%	87.0%	88.1%	88.8%	89.6%	90.3%	90.3%	90.3%
Operating margin	−15.7%	9.6%	12.9%	13.3%	9.8%	13.7%	11.2%	19.0%
Net margin	−7.3%	6.2%	11.4%	10.2%	7.0%	10.5%	10.4%	16.6%
Free-cash-flow margin	15.2%	16.1%	17.8%	18.3%	26.4%	23.4%	19.1%	16.6%
Current ratio	3.30	3.66	3.57	3.85	3.79	3.79	3.90	3.91
R&D as % of revenue	28.7%	14.0%	12.0%	13.4%	17.1%	12.8%	16.8%	11.5%
SG&A as % of revenue	33.1%	31.6%	29.9%	27.2%	28.1%	28.5%	26.2%	22.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · September 30, 2026

What it owns · $983m

Short-term assets $750mLonger-term assets $233m

What it owes, and who funded it · $983m

Short-term liabilities $192mLonger-term liabilities $81mShareholders' equity $710m

Short-term assets cover short-term liabilities $750m of assets due within a year against $192m of liabilities due within a year.
Short-term assets cover long-term liabilities $750m short-term assets against $81m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Kiniksa Pharmaceuticals International, plc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

16 /100

Weak moat

How hard Kiniksa Pharmaceuticals International's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -1.6% of total assets over 9 years.
Durability 10 / 20

Operating margin has been a median -6.8%; its worst year was -18.3%.
Discipline 3 / 20

The diluted share count rose 21.6% over five years; stock-based pay has been a median 7.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (21 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BBIO vs KNSA BCRX vs KNSA IONS vs KNSA KNSA vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kiniksa Pharmaceuticals International, plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kiniksa Pharmaceuticals International, plc.